152 related articles for article (PubMed ID: 11724516)
1. Current topics on immunoadsorption therapy.
Nakaji S
Ther Apher; 2001 Aug; 5(4):301-5. PubMed ID: 11724516
[TBL] [Abstract][Full Text] [Related]
2. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
Yeh JH; Chiu HC
J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
[TBL] [Abstract][Full Text] [Related]
3. Extracorporeal immunoadsorption with IM-PH or IM-TR column.
Yamazaki Z; Idezuki Y; Inoue N; Yoshizawa H; Yamawaki N; Inagaki K; Tsuda N
Biomater Artif Cells Artif Organs; 1989; 17(2):117-24. PubMed ID: 2673426
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion.
Speer C; Kälble F; Pego da Silva L; Nusshag C; Schaier M; Becker LE; Klein K; Beimler J; Sommerer C; Leo A; Süsal C; Mehrabi A; Zeier M; Morath C
Atheroscler Suppl; 2019 Dec; 40():68-72. PubMed ID: 31447215
[TBL] [Abstract][Full Text] [Related]
5. Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: an in vitro study.
Oda S; Hirasawa H; Shiga H; Nakanishi K; Matsuda K; Nakamura M; Ikeda H; Sakai M
Blood Purif; 2004; 22(6):530-6. PubMed ID: 15583478
[TBL] [Abstract][Full Text] [Related]
6. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
Pták J
Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
[TBL] [Abstract][Full Text] [Related]
7. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins.
Koll RA
Ther Apher; 1998 May; 2(2):147-52. PubMed ID: 10225717
[TBL] [Abstract][Full Text] [Related]
8. Immusorba TR and PH.
Hirata N; Kuriyama T; Yamawaki N
Ther Apher Dial; 2003 Feb; 7(1):85-90. PubMed ID: 12921121
[TBL] [Abstract][Full Text] [Related]
9. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis.
Yeh JH; Chiu HC
J Neurol; 2000 Jul; 247(7):510-3. PubMed ID: 10993491
[TBL] [Abstract][Full Text] [Related]
10. Immunoadsorption using Immusorba TR and PH.
Hirano R; Hirata N
Transfus Apher Sci; 2017 Oct; 56(5):661-665. PubMed ID: 28923775
[TBL] [Abstract][Full Text] [Related]
11. Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis.
Hosokawa S; Oyamaguchi A
ASAIO Trans; 1990; 36(3):M207-8. PubMed ID: 2252658
[TBL] [Abstract][Full Text] [Related]
12. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
Takamori M; Maruta T
Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
[TBL] [Abstract][Full Text] [Related]
13. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.
Biesenbach P; Schmaldienst S; Smolen JS; Hörl WH; Derfler K; Stummvoll GH
Atheroscler Suppl; 2009 Dec; 10(5):114-21. PubMed ID: 20129388
[TBL] [Abstract][Full Text] [Related]
14. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber.
Günther C; Laske J; Frind A; Julius U; Pfeiffer C
J Dtsch Dermatol Ges; 2008 Aug; 6(8):661-3. PubMed ID: 18371053
[TBL] [Abstract][Full Text] [Related]
15. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis.
Yeh JH; Chiu HC
J Clin Apher; 1999; 14(4):177-80. PubMed ID: 10611627
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic apheresis in myasthenia gravis patients: a six year follow-up.
Schneidewind JM; Zettl UK; Winkler RE; Ramlow W; Tiess M; Hofmann D; Michelsen A; Weber G; Kinze EM; Adam U; Hauk L; Behnecke R; Klinkmann H
Ther Apher; 1999 Nov; 3(4):298-302. PubMed ID: 10608721
[TBL] [Abstract][Full Text] [Related]
17. The current status of therapeutic apheresis devices in the United States.
Siami GA; Siami FS
Int J Artif Organs; 2002 Jun; 25(6):499-502. PubMed ID: 12117288
[TBL] [Abstract][Full Text] [Related]
18. [Plasmapheresis in patients with myasthenia gravis].
Konishi T
Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of therapeutic effect of extracorporeal detoxication in autoimmune bullous dermatoses].
Grando SA; Glukhen'kiĭ BT; Romanenko AB; Chaiun OA; Dolia SV
Vestn Dermatol Venerol; 1988; (7):6-11. PubMed ID: 3064487
[No Abstract] [Full Text] [Related]
20. A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer.
Fennelly DW; Norton L; Sznol M; Hakes TB
Cancer; 1995 Apr; 75(8):2099-102. PubMed ID: 7697600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
